Literature DB >> 21133595

Association of GSTM1 and GSTT1 gene deletions with risk of head and neck cancer in Pakistan: a case control study.

M Nosheen1, M Ishrat, F A Malik, R M Baig, M A Kayani.   

Abstract

Polymorphic deletions of GSTM1 and GSTT1 genes involved in the detoxification of potentially carcinogenic agents may be risk factors for various cancers, including head and neck cancer (HNC). In the present case-control study we aimed to access possible associations of HNC with GSTM1 and GSTT1 null genotypes in a Pakistani population. DNA was extracted from leukocytes of 388 cancer patients and 150 healthy controls by phenol-chloroform procedure. GSTM1 and GSTT1 deletion variants were genotyped by multiplex PCR assay with CYP1A1 as an internal control and further analyzed by primer specific PCR assay and sequencing. Mean age of cases and controls was 48 (±16.6) years with a male to female ratio of 1:1. Cancer of the oral cavity (57%) was most prevalent in the sampled population followed by pharynx and larynx (30% and 13% respectively). A statistically significant (P<0.05) association was observed for both null genotypes in contribution to HNC as compared with the controls. The odds ratio (OR) for the GSTM1 null genotype was 2.3 with a 95% CI of 1.5-5.5 and for GSTT1 OR was 2.04 with 95% CI of 1.3-3.1. These results suggest that the GSTM1 and GSTT1 null genotypes are risk factors for HNC development among the Pakistani population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21133595

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  11 in total

1.  Association of CYP1A1, GSTM1, and GSTT1 gene polymorphism with risk of oral submucous fibrosis in a section of North Indian population.

Authors:  Tanima Ghosh; Shalini Gupta; Prachi Bajpai; Deepti Agarwal; Mohit Agarwal; O P Gupta; Deepa Agrawal
Journal:  Mol Biol Rep       Date:  2012-07-01       Impact factor: 2.316

Review 2.  Genetic variations and head and neck cancer risks.

Authors:  Nosheen Masood; Azra Yasmin; Mahmood Akhtar Kayani
Journal:  Mol Biol Rep       Date:  2014-01-23       Impact factor: 2.316

3.  Quantitative assessment of the association between GSTM1 null genotype and laryngeal cancer risk.

Authors:  Hui Xiao; Minghua Li; Linli Tian; Bin Zha; Ming Liu; Hongchao Yao
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-13       Impact factor: 2.503

4.  Expression patterns of carcinogen detoxifying genes (CYP1A1, GSTP1 & GSTT1) in HNC patients.

Authors:  Nosheen Masood; Mahmood Akhtar Kayani
Journal:  Pathol Oncol Res       Date:  2012-08-25       Impact factor: 3.201

5.  Glutathione S-transferase T1 null genotype is associated with oral cancer susceptibility in Asian populations.

Authors:  Gang Dong; Yan Tian; Shulan Chen; Xin Xu; Jianjin Zheng; Tao Li
Journal:  Tumour Biol       Date:  2013-04-23

6.  Glutathione S-transferase T1 null genotype and laryngeal cancer risk: a meta-analysis.

Authors:  Qiuying Li; Ming Liu
Journal:  Tumour Biol       Date:  2014-05-31

Review 7.  CYP1A1 and GSTP1 gene variations in breast cancer: a systematic review and case-control study.

Authors:  Sumaira Akhtar; Ishrat Mahjabeen; Zertashia Akram; Mahmood Akhtar Kayani
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

8.  The synergy of tobacco and alcohol and glutathione S-transferase θ 1 gene deletion and oral squamous cell carcinoma.

Authors:  Sarah D' Mello; Radhika Manoj Bavle; K Paremala; Soumya Makarla; M Sudhakara; Madhura Bhatt
Journal:  J Oral Maxillofac Pathol       Date:  2016 Sep-Dec

9.  Protection against laryngeal and pharyngeal carcinoma: Heterozygous vs. homozygous deletions of GSTM1 and GSTT1.

Authors:  Nosheen Masood; Mahmood Akhtar Kayani
Journal:  Genet Mol Biol       Date:  2013-03-04       Impact factor: 1.771

10.  Possible association of a distinct combined Glutathione-S-transferase members with allergic asthma patients in Pakistan.

Authors:  Aamna Dar; Rani Faryal; Nosheen Masood
Journal:  Genes Dis       Date:  2017-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.